Francis Medical Launches Commercial Use of Vanquish System for Prostate Cancer Ablation
Event summary
- Francis Medical completed its first commercial procedure using the Vanquish Water Vapor Ablation System on February 3, 2026, at Pinnacle Surgery Center in Austin, Texas.
- The Vanquish System received 510(k) clearance from the FDA in November 2025, supported by positive 12-month follow-up data from the VAPOR 2 clinical study.
- The VAPOR 2 study demonstrated 91% elimination of targeted intermediate-risk prostate cancer in 110 patients with no device-related serious adverse events.
- The procedure was performed by Dr. Eric Giesler of Urology Austin on a patient with intermediate-risk, localized prostate cancer.
The big picture
Francis Medical's commercial launch of the Vanquish System marks a significant step in the evolution of prostate cancer treatment, offering a minimally invasive alternative with promising efficacy and lower side-effect profiles. The FDA clearance and positive clinical trial results position the company to challenge traditional therapies, potentially reshaping the urological cancer treatment landscape. The success of this technology could drive broader adoption of thermal ablation techniques in oncology.
What we're watching
- Clinical Efficacy
- Whether the Vanquish System can sustain its high efficacy rates in larger commercial populations beyond the clinical trial setting.
- Regulatory Expansion
- The pace at which Francis Medical can secure premarket approval (PMA) for expanded indications, including long-term prostate cancer treatment outcomes.
- Market Adoption
- How quickly the Vanquish System gains traction among urologists and patients seeking minimally invasive alternatives to traditional prostate cancer treatments.
Related topics